ArticleCancer cytopathology2019

HER2 assessment by bright-field dual in situ hybridization in cell blocks of recurrent and metastatic breast carcinoma.

Marcia Edelweiss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.